Treating hypertension in patients with left ventricular dysfunction: Hitting the fairway and avoiding the rough

Current Heart Failure Reports

Volumn 10, Issue 2, 2013, Pages 157-164

  Joffe, Samuel W ^a   Phillips, Robert A ^a,b  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b UMASS MEMORIAL MEDICAL CENTER   (United States)

Author keywords

Aldosterone antagonist; Angiotensin converting enzyme inhibitor; Angiotensin receptor blocker; Beta blocker; Diastolic function; Diuretic; Heart failure; Hypertension; Systolic function; Ventricular dysfunction

Indexed keywords

ALDOSTERONE ANTAGONIST; ALISKIREN; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; CARVEDILOL; CHLORTALIDONE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; EPLERENONE; HYDRALAZINE; IRBESARTAN; LISINOPRIL; LOOP DIURETIC AGENT; METOPROLOL SUCCINATE; NITRATE; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; VALSARTAN; VERAPAMIL;

ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR MORTALITY; CHRONOTROPISM; CLINICAL TRIAL (TOPIC); CORONARY ARTERY DISEASE; DIASTOLIC BLOOD PRESSURE; DIASTOLIC DYSFUNCTION; DISEASE ASSOCIATION; DISEASE COURSE; EXERCISE; GENE EXPRESSION; HEART AFTERLOAD; HEART ATRIUM FIBRILLATION; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE PERFUSION; HEART OUTPUT; HEART PRELOAD; HEMODYNAMICS; HOMEOSTASIS; HUMAN; HYPERTENSION; HYPOTENSION; INOTROPISM; ISCHEMIC CARDIOMYOPATHY; KIDNEY DENERVATION; LOW DRUG DOSE; NONISCHEMIC CARDIOMYOPATHY; PATHOPHYSIOLOGY; RADIOFREQUENCY ABLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SODIUM RESTRICTION; SYSTOLIC BLOOD PRESSURE; SYSTOLIC DYSFUNCTION; WEIGHT REDUCTION;

ANTIHYPERTENSIVE AGENTS; HEART FAILURE; HUMANS; HYPERTENSION; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84883055306     PISSN: 15469530     EISSN: 15469549     Source Type: Journal    
DOI: 10.1007/s11897-013-0137-9     Document Type: Article

References (50)

1. Perera GA. Hypertensive vascular disease; description and natural history. J Chron Dis. 1955;1:33-42.
2. Kannel WB, Castelli WP, McNamara PM, McKee PA, Feinleib M. Role of blood pressure in the development of congestive heart failure - the Framingham study. N Engl J Med. 1972;287:781-7.
3. Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK. The progression from hypertension to congestive heart failure. JAMA. 275(20):1557-62.
4. Hsia J, Margolis KL, Eaton CB, Wenger NK, Allison M, Wu L, et al. Prehypertension and cardiovascular disease risk in the Women's Health Initiative. Circulation. 2007;115(7):855-60.
5. Psaty BM, Lumley T, Furberg CD, Schellenbaum G, Pahor M, Alderman MH, et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA. 2003;289(19):2534-44.
6. Nigel S, Beckett NS, Ruth Peters R, Nigel S, Beckett NS, Ruth Peters R, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358:1887-98.
7. Lee D, Floras J, Newton G, Austin P, Wang X, Liu P, et al. Association of blood pressure at hospital discharge with mortality in patients diagnosed with heart failure. Circ Heart Fail. 2009;2(6):616-23.
8. Muntwyler J, Abetel G, Gruner C, Follath F. One-year mortality among unselected outpatients with heart failure. Eur Heart J. 2002;23(23):1861-6.
9. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293.
10. Pfeffer MA, Braunwald E, Moyé LA, The SAVE Investigators, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. N Engl J Med. 1992;327:669.
11. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999; 353:2001.
12. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet. 2003;362(9386):759-66.
13. Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet. 2003;362(9377):7-13.
14. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991;325:303.
15. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709.
16. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309.
17. •• Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364:11. In this randomized trial of patients with HFrEF with NYHA class II symptoms, the addition of eplerenone to standard therapy reduced mortality by 24%, and reduced hospitalization for HF by 42%.
18. Diez J, Fortuna MA, Ravassa S. Apoptosis in hypertensive heart disease. Curr Opin Cardiol. 1998;13:317-25.
19. Drazner MH, Rame JE, Marino EK, Gottdiener JS, Kitzman DW, Gardin JM, et al. Increased left ventricular mass is a risk factor for the development of a depressed left ventricular ejection fraction within five years: the Cardiovascular Health Study. J Am Coll Cardiol. 2004;43:2207-15.
20. Shapiro BP, Owan TE, Mohammed S, Kruger M, Linke WA, Burnett JC, et al. Mineralocorticoid signaling in transition to heart failure with normal ejection fraction. Hypertension. 2008;51:289-95.
21. Ahmed SH, Clark LL, Pennington WR, Webb CS, Bonnema DD, Leonardi AH, et al. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structure, functional, and clinical manifestations of hypertensive heart disease. Circulation. 2006;113:2089-96.
22. Zile MR, Bennett TD, St John Sutton M, Cho YK, Adamson PB, Aaron MF, et al. Transition from chronic compensated to acute decompensated heart failure: pathophysiological insights obtained from continuous monitoring of intracardiac pressures. Circulation. 2008;118:1433-41.
23. Melenovsky V, Borlaug BA, Rosen B, Hay I, Ferruci L, Morell CH, et al. Cardiovascular features of heart failure with preserved ejection fraction versus nonfailing hypertensive left ventricular hypertrophy in the urban Baltimore community: the role of atrial remodeling/dysfunction. J Am Coll Cardiol. 2007;49(2):198-207. Epub 2006 Dec 29.
24. Lam CS, Roger VL, Rodeheffer RJ, Bursi F, Borlaug BA, Ommen SR, et al. Cardiac structure and ventricular-vascular function in persons with heart failure and preserved ejection fraction from Olmsted County, Minnesota. Circulation. 2007;115(15):1982-90.
25. Borlaug BA, Lam CS, Roger VL, Rodeheffer RJ, Redfield MM. Contractility and ventricular systolic stiffening in hypertensive heart disease insights into the pathogenesis of heart failure with preserved ejection fraction. J Am Coll Cardiol. 2009;54(5):410-8.
26. Moser M, Hebert PR. Prevention of disease progression, left ventricular hypertrophy and congestive heart failure in hypertension treatment trials. J Am Coll Cardiol. 1996;27(5):1214-8.
27. Greenberg B, Quinones MA, Koilpillai C, Limacher M, Shindler D, Benedict C, et al. Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction. Results of the SOLVD echocardiography substudy. Circulation. 1995;91(10):2573-81.
28. Longobardi G, Ferrara N, Furgi G, Abete P, Rengo F. Improvement of myocardial blood flow to ischemic regions by angiotensin-converting enzyme inhibition. J Am Coll Cardiol. 2000;36(4):1437-8.
29. Minai K, Matsumoto T, Horie H, Ohira N, Takashima H, Yokohama H, et al. Bradykinin stimulates the release of tissue plasminogen activator in human coronary circulation: effects of angiotensin-converting enzyme inhibitors. J Am Coll Cardiol. 2001;37(6):1565-70.
30. Packer M, Poole-Wilson PA, Armstrong PW, Cleland JG, Horowitz JD, Massie BM, et al. Comparative effects of low and high doses of the angiotensin- converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation. 1999;100(23):2312-8.
31. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Køber L, Maggioni AP, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349(20):1893-906.
32. Weir RA, McMurray JJ, Puu M, Solomon SD, Olofsson B, Granger CB, et al. Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial. Eur J Heart Fail. 2008;10(2):157-63.
33. Cohn JN, Pfeffer MA, Rouleau J, Sharpe N, Swedberg K, Straub M, et al. Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON). Eur J Heart Fail. 2003;5(5):659-67.
34. ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs. chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA. 2000;283(15):1967-75.
35. U.S. Food and Drug Administration. Aliskiren-containing medications: Drug safety communication - new warning and contraindication. 2012.
36. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003;362(9386):777-81.
37. Solomon SD, Janardhanan R, Verma A, Bourgoun M, Daley WL, Purkayastha D, et al. Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial. Lancet. 2007;369(9579):2079-87.
38. Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008;359(23):2456-67.
39. • Solomon SD, Verma A, Desai A, Hassanein A, Izzo J, Oparil S, et al. Effect of intensive versus standard blood pressure lowering on diastolic function in patients with uncontrolled hypertension and diastolic dysfunction. Hypertension. 2010;55(2):241-8. In this randomized trial of patients with HFpEF and uncontrolled hypertension, improvements in diastolic function as measured by echocardiographic parameters correlated with the degree of blood pressure reduction achieved.
40. Phillips RA, Goldman ME, Ardeljan M, Arora R, Eison HB, Yu BY, et al. Determinants of abnormal left ventricular filling in early hypertension. J Am Coll Cardiol. 1989;14(4):979-85.
41. Hunt SA, Abraham WT, Chin MH, et al. Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009;119:e391.
42. Belardinelli R, Georgiou D, Cianci G, Purcaro A. 10-year exercise training in chronic heart failure: a randomized controlled trial. J Am Coll Cardiol. 2012;60(16):1521-8.
43. O'Connor CM, Whellan DJ, Lee KL, Keteyian SJ, Cooper LS, Ellis SJ, et al. Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA. 2009;301(14):1439-50.
44. • Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Böhm M, et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet. 2010;376(9756):1903-9. In this landmark, randomized trial in patients with resistant hypertension, catheter-based renal denervation therapy resulted in a reduction in blood pressure of 32/12 mmHg at 6 months, with no significant complication or adverse event.
45. • Brandt MC, Mahfoud F, Reda S, Schirmer SH, Erdmann E, Böhm M, et al. Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension. J Am Coll Cardiol. 2012;59(10):901-9. In patients with resistant hypertension, LVH, and diastolic dysfunction treated with catheter-based renal denervation therapy, this study demonstrated significant reduction in LVH and improvement in diastolic function based on echocardiographic parameters.
46. Fagard RH, Staessen JA, Thijs L, Celis H, Bulpitt CJ, de Leeuw PW, et al. On-treatment diastolic blood pressure and prognosis in systolic hypertension. Arch Intern Med. 2007;167(17):1884-91.
47. Rosendorff C et al. Treatment of hypertension in the prevention and management of ischemic heart disease. Circulation. 2007;115:2761-88.
48. Pepine CJ et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease: the International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA. 2003;290:2805-16.
49. • Anderson JL et al. ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the management of patients with unstable angina/non-ST-Elevation Myocardial Infarction: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 123. 2011. This update to ACC-AHA guidelines suggests a blood pressure goal of <140/90 mmHg for based on JNC-7, and <130/80 mmHg for patients with diabetes or chronic kidney disease.
50. Bangalore S et al. Pulse pressure and risk of cardiovascular outcomes in patients with hypertension and coronary artery disease: an International VErapamil SR-trandolapril Study (INVEST) analysis. Eur Heart J. 2009;30:1395-401.